<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383344</url>
  </required_header>
  <id_info>
    <org_study_id>06-086</org_study_id>
    <nct_id>NCT00383344</nct_id>
  </id_info>
  <brief_title>Use of FDG PET/CT to Evaluate Crohn Disease</brief_title>
  <official_title>Phase II Study on the Role of the Positron Emission Tomography Combined With CT Scan for the Evaluation on Crohn Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <brief_summary>
    <textblock>
      The purpose of this study will permit to determine the role of FDG PET/CT to diagnose Crohn&#xD;
      Disease and recurrence of Crohn disease after having compared results of PET/CT's with&#xD;
      results of exams routinely performed(colonoscopy and bowel follow through).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Crohn disease is an inflammatory disease of the digestive system that may affect the small&#xD;
      and large intestines. Remission and recurrence clinically characterized its development. When&#xD;
      recurrence occurs, a careful examination is necessary in order to determine the extent and&#xD;
      the severity of the disease. Actual exams performed are invasive and&#xD;
      uncomfortable(colonoscopy and bowel follow through). Compare to these exams, PET/CT is less&#xD;
      fierce to undergo and has less risks. Two groups are proposed in this project: 15 patients&#xD;
      will be enroll in the active disease group and 15 patients will be enroll in the remission&#xD;
      group. In regards of the area and the extent of the disease,PET/CT exams shall provide&#xD;
      similar information than what usual tests provide. PET/CT exams shall also provide more&#xD;
      information in order to better differentiate inflammatory stenosis from scars stenosis&#xD;
      especially located in the small intestine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <completion_date>May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of Crohn Disease de novo and Crohn Disease recurrences with FDG PET/CT.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of inflammatory areas not suspected with usual tests</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of an inflammatory activity for remission patients</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Crohn Disease</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FDG PET/CT</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women known having a Crohn's disease de novo diagnosis or a Crohn's disease&#xD;
             recurrence based on a seven days questionnaire and a physical exam.&#xD;
&#xD;
          -  Men or women with a past history of Crohn's disease but considered clinically in&#xD;
             remission based on a seven days questionnaire, a physical exam and a Crohn's disease&#xD;
             activity index (CDAI) score &lt; to 150.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men or women less than 18 years of age&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Suspicion of a Crohn's disease infectious complication (abscess,fistula)&#xD;
&#xD;
          -  Infectious colitis determined at the initial checkup&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Severe allergy to iode contrast&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Bénard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Bénard, Doctor</last_name>
    <phone>819 346-1110</phone>
    <phone_ext>11898</phone_ext>
    <email>francois.benard@usherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chantal Langevin, RN</last_name>
    <phone>819 346-1110</phone>
    <phone_ext>12887</phone_ext>
    <email>chantal.langevin@chus.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHUS/CRC</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Bénard, DR</last_name>
      <phone>819 346-1110</phone>
      <phone_ext>11868</phone_ext>
      <email>francois.benard@usherbrooke.ca</email>
    </contact>
    <contact_backup>
      <last_name>Chantal Langevin, RN, coordinator</last_name>
      <phone>819 346-1110</phone>
      <phone_ext>12887</phone_ext>
      <email>chantal.langevin@chus.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>François Bénard, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge Langevin, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivianne Bergeron, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerard Schmutz, DR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Turcotte, DR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>October 2, 2006</study_first_submitted>
  <study_first_submitted_qc>October 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <last_update_submitted>April 5, 2007</last_update_submitted>
  <last_update_submitted_qc>April 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2007</last_update_posted>
  <keyword>Crohn Disease</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Colonoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

